sure and that could happen at any point, but a buyout probably doesn't happen until the CD trial reads out unless there is a CVR built in incidentally the plantar fasciitis primary endpoint is 8 weeks out and the company guided that enrollment will be complete this year. that suggests data early in 2020 not second half (and in fact the prior phase 2 completed enrollment in october and read out 3 months later). Just something else to look out for as a possible catalyst near term